State and Territory Attorneys General Urge FDA to Take Action Against Counterfeit and Illegally Sold GLP-1 Drugs
Washington, D.C.– The National Association of Attorneys General (NAAG) sent a letter on behalf of a bipartisan coalition of 38 state and territory attorneys general which calls on the Food and Drug Administration (FDA) to take decisive action against the unlawful sale and distribution of counterfeit and illegally sold GLP-1 drugs, including Mounjaro, Zepbound, Ozempic, and…
2022 NAAG Legislative Victories
As the chief legal officer of their state, attorneys general often provide important input on both regulatory and legislative proposals. This input is often provided through the National Association of Attorneys General (NAAG). As a nonpartisan organization, NAAG engages in policy advocacy only when an issue has bipartisan support from a majority of attorneys general….
NAAG Urges DEA and SAMSHA to Extend Telehealth Capabilities for Opioid Use Disorder Treatment
A bipartisan group of 45 state attorneys general urge the Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA) to permanently extend telehealth flexibilities after the expiration of the public health emergency for prescribing buprenorphine, one of three Food and Drug Administration (FDA) approved medications for treating opioid use disorder. Buprenorphine…
Current Status of COVID-19 Vaccines Rollout Nationwide: July 2022 Update for the Attorney General Community
On July 13, the U.S. reached over 222.6 million persons (67.1% of the total U.S. population) having received their primary COVID-19 vaccine series (i.e., having received either one shot of the Johnson & Johnson/Janssen vaccine or two shots of either the mRNA Pfizer/BioNTech or Moderna vaccines). Nearly 400,000 children under five years of age have…
Current Status of COVID-19 Vaccines Rollout Nationwide: June 2022 Update for the Attorney General Community
On June 17, the U.S. reached nearly 221.9 million persons (66.8% of the total U.S. population) having received their primary COVID-19 vaccine series (i.e., having received either one shot of the Johnson & Johnson/Janssen vaccine or two shots of either the mRNA Pfizer/BioNTech or Moderna vaccines). Over 104.7 million persons in the U.S. have received…
Current Status of COVID-19 Vaccines Rollout Nationwide: May 2022 Update for the Attorney General Community
On May 16, the U.S. reached nearly 220.6 million persons (66.4% of the total U.S. population) having received their primary COVID-19 vaccine series (i.e., having received either one shot of the Johnson & Johnson/Janssen vaccine or two shots of either the mRNA Pfizer/BioNTech or Moderna vaccines). Over 102 million persons in the U.S. have received…
